Champions Biotechnology, a developer of advanced preclinical platforms and tumor specific data designed to enhance and accelerate the
value of oncology drugs, will deploy its Biomerk Tumorgraft platform to guide development of new oncology therapeutics.
The platform enables identification of the most promising development path possible cancer therapies in terms of indication, drug combination, and target patient population. The platform also has the potential to identify gene pathways of response and resistance as well as prognostic molecular biomarkers.
"We are excited to continue the growth of our impressive client base and begin working with one of the most respected global leaders in the discovery and development of novel therapies," says Doug Burkett, Ph.D., President of Champions Biotechnology, Inc.
"Studies suggest that evaluation of oncology compounds through our Biomerk Tumorgraft platform will lead to more successful and efficient clinical development. The value-added by an optimally targeted, more efficient clinical path can result in cost savings, improved clinical and commercial success and significantly more years of patent life following commercialization," he adds.
Writer: Walaika Haskins
Source: Doug Burkett, Champions Biotechnology, Inc.